avian flu page 16 at
http://www.timebomb2000.com/vb/showthread.php?p=1576159#post1576159
Reports of Tamiflu resistance to avian flu based on old data, not new proof
Helen Branswell
Canadian Press
Friday, October 07, 2005
TORONTO (CP) - It appears a misunderstanding, not a mutation, is behind recent reports suggesting the H5N1 avian flu strain is developing resistance to the drug Tamiflu.
The professor of pharmacology from Hong Kong University quoted as warning of an emerging resistant strain of the virus says he was citing old data, not new evidence, when he gave an interview last week.
He was trying to urge GlaxoSmithKline to reintroduce an injectable form of their rival flu drug, Relenza. The resulting report suggested Tamiflu was becoming less useful - a claim that was widely repeated.
"My point is to emphasize on the introduction of injectable drugs. But they use a headline 'Resistant H5N1 appears in Vietnam,' " Dr. William Chui, who is also chief of the pharmacy service of Hong Kong's Queen Mary Hospital, said in an interview.
"I'm not the right channel to say that."
Chui says he was citing medical literature, including a recent New England Journal of Medicine review article on human cases of avian influenza that made reference to an H5N1 isolate from Vietnam shown to be partially resistant to oseltamivir, Tamiflu's generic name.
That discovery was made public in mid-May in the report of a meeting of experts the World Health Organization convened in Manila to determine whether the pandemic risk from H5N1 had risen.
When the reports quoting Chui started to circulate, flu experts around the world sent out urgent e-mails trying to find out who had found new evidence of resistance. The flu community keeps close tabs on the efficacy of these important drugs, known as neuraminidase inhibitors.
They came up with a puzzling blank.
Except for that one partially resistant H5N1 isolate from Vietnam, no researchers have reported new discoveries of Tamiflu-resistant viruses isolated from human cases of H5N1, both the WHO and Tamiflu's manufacturer, Hoffman-La Roche confirm.
"There is a network of laboratories that has been set up to follow antiviral resistance among influenza strains," says Michael Perdue, a scientist in the WHO's global influenza program.
"One of the first things they look at (when they get new viral isolates) is the antiviral sensitivity and resistance. And the papers that have been published thus far have shown all the strains to be sensitive."
That doesn't mean there might not be evidence of resistance out there, being kept under wraps by researchers pushing them through the publication pipeline of medical journals.
Still, Perdue thinks word might have gotten around.
"There's no hard and fast rule. But generally people let WHO know information like that. And we have not heard."
Neither has Roche, which has stewed while reports have questioned the value of their drug.
Oseltamivir is one of only two drugs thought to be effective against H5N1; Relenza is the other. Governments around the world have been rushing to stockpile the easier-to-administer Tamiflu as a hedge against a possible pandemic. (Tamiflu is sold in pills; Relenza is inhaled like an asthma drug.)
"We don't have additional (resistance) data so when we see articles like this, we're as perplexed as everyone else," says Paul Brown, a vice-president of Roche Canada and until recently global team leader for Tamiflu.
However, everyone, including Roche, expects some resistance to the drug to develop if it becomes widely used. In fact, studies have shown just that in Japan, the only market to date which has embraced Tamiflu in a serious way for seasonal influenza.
Antiviral researcher Dr. Frederick Hayden of the University of Virginia says a recent study of Japanese children showed about 16 per cent developed resistance to the drug.
"That's one in six. So I would anticipate that in H5N1-infected persons that the frequency would certainly be no less," says Hayden, co-chair of an international network of scientists who monitor for resistance to neuraminidase inhibitors.
But even when resistance develops, evidence suggests it may not spread easily. In the lab, viruses that develop resistance to oseltamivir pay a price; they are less fit than non-resistant viruses.
That suggests it might be difficult for a resistant strain of the virus to emerge and claim dominance over non-resistance strains.
So far the evidence that resistance strains are less fit has been shown only with human flu strains, Hayden says. But studies could and should be done to see if the same holds true with H5N1 viruses, he insists.
http://www.canada.com/components/printstory/printstory4.aspx?id=81201e24-9e91-4287-833b-9da02ff083ac
http://www.timebomb2000.com/vb/showthread.php?p=1576159#post1576159
Reports of Tamiflu resistance to avian flu based on old data, not new proof
Helen Branswell
Canadian Press
Friday, October 07, 2005
TORONTO (CP) - It appears a misunderstanding, not a mutation, is behind recent reports suggesting the H5N1 avian flu strain is developing resistance to the drug Tamiflu.
The professor of pharmacology from Hong Kong University quoted as warning of an emerging resistant strain of the virus says he was citing old data, not new evidence, when he gave an interview last week.
He was trying to urge GlaxoSmithKline to reintroduce an injectable form of their rival flu drug, Relenza. The resulting report suggested Tamiflu was becoming less useful - a claim that was widely repeated.
"My point is to emphasize on the introduction of injectable drugs. But they use a headline 'Resistant H5N1 appears in Vietnam,' " Dr. William Chui, who is also chief of the pharmacy service of Hong Kong's Queen Mary Hospital, said in an interview.
"I'm not the right channel to say that."
Chui says he was citing medical literature, including a recent New England Journal of Medicine review article on human cases of avian influenza that made reference to an H5N1 isolate from Vietnam shown to be partially resistant to oseltamivir, Tamiflu's generic name.
That discovery was made public in mid-May in the report of a meeting of experts the World Health Organization convened in Manila to determine whether the pandemic risk from H5N1 had risen.
When the reports quoting Chui started to circulate, flu experts around the world sent out urgent e-mails trying to find out who had found new evidence of resistance. The flu community keeps close tabs on the efficacy of these important drugs, known as neuraminidase inhibitors.
They came up with a puzzling blank.
Except for that one partially resistant H5N1 isolate from Vietnam, no researchers have reported new discoveries of Tamiflu-resistant viruses isolated from human cases of H5N1, both the WHO and Tamiflu's manufacturer, Hoffman-La Roche confirm.
"There is a network of laboratories that has been set up to follow antiviral resistance among influenza strains," says Michael Perdue, a scientist in the WHO's global influenza program.
"One of the first things they look at (when they get new viral isolates) is the antiviral sensitivity and resistance. And the papers that have been published thus far have shown all the strains to be sensitive."
That doesn't mean there might not be evidence of resistance out there, being kept under wraps by researchers pushing them through the publication pipeline of medical journals.
Still, Perdue thinks word might have gotten around.
"There's no hard and fast rule. But generally people let WHO know information like that. And we have not heard."
Neither has Roche, which has stewed while reports have questioned the value of their drug.
Oseltamivir is one of only two drugs thought to be effective against H5N1; Relenza is the other. Governments around the world have been rushing to stockpile the easier-to-administer Tamiflu as a hedge against a possible pandemic. (Tamiflu is sold in pills; Relenza is inhaled like an asthma drug.)
"We don't have additional (resistance) data so when we see articles like this, we're as perplexed as everyone else," says Paul Brown, a vice-president of Roche Canada and until recently global team leader for Tamiflu.
However, everyone, including Roche, expects some resistance to the drug to develop if it becomes widely used. In fact, studies have shown just that in Japan, the only market to date which has embraced Tamiflu in a serious way for seasonal influenza.
Antiviral researcher Dr. Frederick Hayden of the University of Virginia says a recent study of Japanese children showed about 16 per cent developed resistance to the drug.
"That's one in six. So I would anticipate that in H5N1-infected persons that the frequency would certainly be no less," says Hayden, co-chair of an international network of scientists who monitor for resistance to neuraminidase inhibitors.
But even when resistance develops, evidence suggests it may not spread easily. In the lab, viruses that develop resistance to oseltamivir pay a price; they are less fit than non-resistant viruses.
That suggests it might be difficult for a resistant strain of the virus to emerge and claim dominance over non-resistance strains.
So far the evidence that resistance strains are less fit has been shown only with human flu strains, Hayden says. But studies could and should be done to see if the same holds true with H5N1 viruses, he insists.
http://www.canada.com/components/printstory/printstory4.aspx?id=81201e24-9e91-4287-833b-9da02ff083ac